{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:21Z","timestamp":1787021061202,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of cannabis for treating fibromyalgia syndrome (FMS) has not been comprehensively investigated. Thus, we have assessed the efficacy and adverse events (AEs) of short- and long-term medical cannabis (MC) treatment for FMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from medical reports archived in the pain clinic of Ponderano (Italy; retrospective study). FMS patients, who were resistant to conventional therapy, received licensed MC with various \u0394-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) content, as powdered whole flowers (decoction or vaporization) or oil extracts. Demographic and clinical parameters, including Numerical Rating Scale (NRS), Oswestry Disability Index (ODI), Hospital Anxiety and Depression Scale, Widespread Pain Index (WPI), Severity Score (SyS), and side effects, were obtained after 1, 3, and 12 months. Data were analyzed with Wilcoxon signed-rank tests for paired data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-eight patients were included. Thirty, 18, and 12 patients continued therapy for 1, 3, and 12 months, respectively. Significant improvements (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01) were observed in NRS, ODI, WPI, and SyS at 1 month; in NRS, ODI, and WPI at 3 months; and in NRS, ODI, and SyS at 12 months. Therapy was interrupted by 17 patients (48.6%) owing to nonserious AEs according to the FDA. The most common side effects were mental confusion (37%), dizziness (14%), nausea\/vomiting (14%), and restlessness\/irritation (14%). The median daily dose of milled flowers administered as THC-dominant MC and hybrid MC (with similar THC\/CBD ratio) was 200 mg\/day and 400 mg\/day, respectively. After 3 months of titration, the median content of THC administered with THC-dominant MC cultivars was 46.2 mg, and of THC + CBD administered as a hybrid MC cultivar, was 23.6 mg + 38 mg. At 3 months, median THC content administered in the oil extract of the THC-dominant MC cultivars was 9.7 mg, while that of THC + CBD administered in the oil extract of the hybrid MC cultivars was 1.8 mg + 2 mg.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MC may represent an alternative treatment for patients with FMS who are unresponsive to conventional therapy. However, its application may be limited by the incidence of nonserious AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-021-00060-6","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:38:20Z","timestamp":1613781500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0366","authenticated-orcid":false,"given":"Manuela","family":"Mazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"60_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","volume":"16","author":"MH Andreae","year":"2015","unstructured":"Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16:1221\u201332.","journal-title":"J Pain"},{"key":"60_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.37842","volume":"65","author":"LM Arnold","year":"2013","unstructured":"Arnold LM, Fan J, Iyengar SK. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis Rheumatol. 2013;65:1122\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"60_CR3","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain Management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755\u201396.","journal-title":"Pain Physician"},{"key":"60_CR4","series-title":"CADTH Rapid Response Report: Summary with Critical Appraisal","volume-title":"Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines","author":"S Banerjee","year":"2019","unstructured":"Banerjee S, McCormack S. Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines, CADTH Rapid Response Report: Summary with Critical Appraisal. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019."},{"key":"60_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00213-010-1995-4","volume":"212","author":"G Bedi","year":"2010","unstructured":"Bedi G, Foltin RW, Gunderson EW. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology (Berl). 2010;212:675\u201386.","journal-title":"Psychopharmacology (Berl)"},{"key":"60_CR6","first-page":"426130","volume":"2012","author":"E Bellato","year":"2012","unstructured":"Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, Blonna D. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis and treatment. Pain Res Treat. 2012;2012:426130.","journal-title":"Pain Res Treat"},{"key":"60_CR7","doi-asserted-by":"publisher","first-page":"R120","DOI":"10.1186\/ar2783","volume":"11","author":"RM Bennet","year":"2009","unstructured":"Bennet RM, Friend R, Jones KD. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:R120.","journal-title":"Arthritis Res Ther"},{"key":"60_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/SAR.S109576","volume":"8","author":"U Bonnet","year":"2017","unstructured":"Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9\u201337.","journal-title":"Subst Abuse Rehabil"},{"key":"60_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.semarthrit.2008.12.003","volume":"39","author":"JC Branco","year":"2010","unstructured":"Branco JC, Bannwarth B, Failde I, Carnbonell JA. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39:448\u201353.","journal-title":"Semin Arthritis Rheum"},{"key":"60_CR10","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1002\/art.38178","volume":"65","author":"CM Brummett","year":"2013","unstructured":"Brummett CM, Goesling J, Tsodikov A, Meraj TS, Wasserman RA, Clauw DJ, Hassett AL. Prevalence of the fibromyalgia phenotype in spine pain patients presenting to a tertiary care pain clinic and the potential treatment implications. Arthritis Rheum. 2013;65:3285\u201392. https:\/\/doi.org\/10.1002\/art.38178.","journal-title":"Arthritis Rheum."},{"key":"60_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s005200050241","volume":"7","author":"M Costantini","year":"1999","unstructured":"Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999;7:121\u20137. https:\/\/doi.org\/10.1007\/s005200050241.","journal-title":"Support Care Cancer."},{"key":"60_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0b013e31820c23fa","volume":"5","author":"RD Crean","year":"2011","unstructured":"Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1\u20138.","journal-title":"J Addict Med"},{"key":"60_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1300\/J094v10n01_15","volume":"10","author":"PR Croft","year":"2002","unstructured":"Croft PR. The epidemiology of chronic widespread pain. J Musculoskelet Pain. 2002;10:191\u20139.","journal-title":"J Musculoskelet Pain"},{"key":"60_CR14","unstructured":"Decreto ministeriale 23 gennaio 2013. Aggiornamento delle tabelle contenenti l'indicazione delle sostanze stupefacenti e psicotrope, di cui al decreto del Presidente della Repubblica 9 ottobre 1990, n. 309 e successive modificazioni e integrazioni. Inserimento nella Tabella II, Sezione B, dei medicinali di origine vegetale a base di Cannabis (sostanze e preparazioni vegetali, inclusi estratti e tinture). [Italian law: Ministerial decree 23rd January 2013. Update of tables containing the indication of narcotics and psychotropic substances, from Republic President decree 9th of October 1990, n 309 and subsequent modifications and integrations. Inclusion in Table II, Section B, of Cannabis plant derived drugs (vegetal substances and preparations, including extracts and titures.]"},{"key":"60_CR15","first-page":"e372","volume":"61","author":"A Deshpande","year":"2015","unstructured":"Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician. 2015;61:e372\u201381.","journal-title":"Can Fam Physician"},{"key":"60_CR16","volume-title":"Handbook of Cannabis","author":"M ElSohly","year":"2014","unstructured":"ElSohly M, Gul W. Constituents of Cannabis sativa. In: Pertwee R, editor. Handbook of Cannabis. Oxford: Oxford University press; 2014."},{"key":"60_CR17","doi-asserted-by":"publisher","first-page":"e18440","DOI":"10.1371\/journal.pone.0018440","volume":"6","author":"J Fiz","year":"2011","unstructured":"Fiz J, Duran M, Capella D, Carbonell J, Farr\u00e9 M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. Plos One. 2011;6:e18440. https:\/\/doi.org\/10.1371\/journal.pone.0018440.","journal-title":"Plos One"},{"key":"60_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J175v04n01_02","volume":"4","author":"D Gieringer","year":"2008","unstructured":"Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2008;4:7\u201327.","journal-title":"J Cannabis Ther."},{"key":"60_CR19","volume-title":"Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potentials","author":"F Grotenhermen","year":"2002","unstructured":"Grotenhermen F, Russo E. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potentials. Abingdon: Routledge; 2002."},{"key":"60_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/RHU.0000000000000702","volume":"24","author":"G Habib","year":"2018","unstructured":"Habib G, Artul S. Medical Cannabis for the treatment of fibromyalgia. J Clin Rheumatol. 2018;24:255\u20138.","journal-title":"J Clin Rheumatol"},{"key":"60_CR21","first-page":"7829427","volume":"2018","author":"G Habib","year":"2018","unstructured":"Habib G, Avisar I. The consumption of Cannabis by fibromyalgia patients in Israel. Pain Res Treat. 2018;2018:7829427.","journal-title":"Pain Res Treat"},{"key":"60_CR22","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","volume":"15","author":"M Haefeli","year":"2006","unstructured":"Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15:S17\u201324.","journal-title":"Eur Spine J"},{"key":"60_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/AJP.0000000000000364","volume":"32","author":"S Haroutounian","year":"2016","unstructured":"Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32:1036\u201343.","journal-title":"Clin J Pain"},{"key":"60_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jep.2007.05.019","volume":"113","author":"A Hazekamp","year":"2007","unstructured":"Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol. 2007;113:85\u201390.","journal-title":"J Ethnopharmacol."},{"key":"60_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2147\/JPR.S98182","volume":"9","author":"GD Ko","year":"2016","unstructured":"Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis\u2013the Canadian perspective. J Pain Res. 2016;9:735\u201344.","journal-title":"J Pain Res"},{"key":"60_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00213-014-3749-1","volume":"232","author":"MA Kowal","year":"2015","unstructured":"Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, van der Wee NJA, Durieux J, Manai M, Hommel B. Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users. Psychopharmacology. 2015;232:1123\u201334.","journal-title":"Psychopharmacology"},{"key":"60_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","volume-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"M Lunn","year":"2014","unstructured":"Lunn M, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. London: The Cochrane Library; 2014."},{"key":"60_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2016","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E, Choi E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Lonley K, McCarthy M, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2016;76:318.","journal-title":"Ann Rheum Dis"},{"key":"60_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/40.1.95","volume":"40","author":"J Mc Beth","year":"2001","unstructured":"Mc Beth J, Macfarlane GJ, Hunt IM, Silman AJ. Risk factors for persistent chronic widespread pain: a community-based study. Rheumatology. 2001;40:95\u2013101.","journal-title":"Rheumatology"},{"key":"60_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1021\/cr60299a002","volume":"76","author":"R Mechoulam","year":"1976","unstructured":"Mechoulam R, Mc Callum NK, Burstein S. Recent advances in the chemistry and biochemistry of Cannabis. Chem Rev. 1976;76:75\u2013112.","journal-title":"Chem Rev"},{"key":"60_CR31","doi-asserted-by":"publisher","first-page":"20190","DOI":"10.1097\/BRS.0b013e3181aa1e6b","volume":"34","author":"M Monticone","year":"2009","unstructured":"Monticone M, Baiardi P, Ferrari S, Foti C. Development of the Italian version of the Oswestry disability index (ODI-I): a cross-cultural adaptation, reliability and validity study. Spine. 2009;34:20190\u20135.","journal-title":"Spine"},{"key":"60_CR32","doi-asserted-by":"publisher","first-page":"CD012182","DOI":"10.1002\/14651858.CD012182.pub2","volume":"2018","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;2018:CD012182. https:\/\/doi.org\/10.1002\/14651858.CD012182.pub2.","journal-title":"Cochrane Database Syst Rev."},{"key":"60_CR33","unstructured":"National Pain Report (2014) Marijuana rated most effective for treating fibromyalgia. National Pain Report. http:\/\/nationalpainreport.com\/marijuana-rated-most-effective-for-treating-fibromyalgia-8823638.html. Accessed 15 Jan 2020."},{"key":"60_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/j.pain.0000000000000899","volume":"158","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, Beals ML, Abess AT, Nichols D, Martin M, Cobb CM, DeKeuster RM. Chronic pain patients\u2019 perspectives of medical cannabis. Pain. 2017;158:1373\u20139.","journal-title":"Pain"},{"key":"60_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","volume":"17","author":"L Queiroz","year":"2013","unstructured":"Queiroz L. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17:356.","journal-title":"Curr Pain Headache Rep"},{"key":"60_CR36","unstructured":"REGIONE PIEMONTE BU8S1 25\/02\/2016. Deliberazione della Giunta Regionale 15 febbraio 2016, n. 24-2920 Indirizzi procedurali ed organizzativi per l'attuazione della Legge Regionale n. 11 del 15 giugno 2015 - Uso terapeutico della canapa. [Regional law: Piedmont Region BU8S1 25\/02\/2016. Resolution of regional government 15 February 2016, n 24-2920. Procedural and organizational guidelines for the implementation of the regional law n. 11 15th June 2015 \u2013 Therapeutic use of hemp.]"},{"key":"60_CR37","first-page":"1","volume":"1","author":"L Romano","year":"2013","unstructured":"Romano L, Hazekamp A. Cannabis oil: evaluation of an upcoming cannabis-based medicine. Cannabinoids. 2013;1:1\u201311.","journal-title":"Cannabinoids"},{"key":"60_CR38","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/jcm8060807","volume":"8","author":"I Sagy","year":"2019","unstructured":"Sagy I, Bar-Lev L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8:807.","journal-title":"J Clin Med"},{"key":"60_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2011.98","volume":"7","author":"T Schmidt-Wilcke","year":"2011","unstructured":"Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011;7:518\u201327.","journal-title":"Nat Rev Rheumatol"},{"key":"60_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek RQ, Galimova I, Ethansand Dary K. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164\u201373.","journal-title":"J Pain"},{"key":"60_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/02791072.2015.1074766","volume":"47","author":"WD Troutt","year":"2015","unstructured":"Troutt WD, DiDonato MD. Medical cannabis in Arizona: patient characteristics, perceptions and impressions of medical cannabis legalization. J Psychoactive Drugs. 2015;47:259\u201366.","journal-title":"J Psychoactive Drugs"},{"key":"60_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010782","volume-title":"Anticonvulsants for fibromyalgia","author":"N \u00dc\u00e7eyler","year":"2013","unstructured":"\u00dc\u00e7eyler N, Sommer C, Walitt B, H\u00e4user W. Anticonvulsants for fibromyalgia. London: The Cochrane Library; 2013."},{"key":"60_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160:860\u20139.","journal-title":"Pain"},{"key":"60_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acr.21896","volume":"65","author":"A Vincent","year":"2013","unstructured":"Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, Sauver JS. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester epidemiology project. Arthritis Care Res. 2013;65:786\u201392.","journal-title":"Arthritis Care Res"},{"key":"60_CR45","first-page":"CD011694","volume":"7","author":"B Walitt","year":"2016","unstructured":"Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694.","journal-title":"Cochrane Database Syst Rev."},{"key":"60_CR46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, Fitzcharles MA, Joseph I, Shir Y. The effect of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anaesth Analg. 2010;110:604\u201310.","journal-title":"Anaesth Analg"},{"key":"60_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/acr.21931","volume":"65","author":"F Wolfe","year":"2013","unstructured":"Wolfe F, Brahler E, Hinz A, Hauser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res. 2013;65:777\u201385.","journal-title":"Arthritis Care Res"},{"key":"60_CR48","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3899\/jrheum.141519","volume":"42","author":"F Wolfe","year":"2015","unstructured":"Wolfe F, Brian BD, Walitt MD, Hauser W. The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol. 2015;42:1494\u2013501.","journal-title":"J Rheumatol"},{"key":"60_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease P, Russell AS, Russell IJ, Walitt B. Revision to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheumatol. 2016;46:319\u201329.","journal-title":"Semin Arthritis Rheumatol"},{"key":"60_CR50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Rheumatol. 2010;62:600\u201310.","journal-title":"Arthritis Rheumatol"},{"key":"60_CR51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3899\/jrheum.100594","volume":"38","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38:1113\u201322.","journal-title":"J Rheumatol"},{"key":"60_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.1780380104","volume":"38","author":"F Wolfe","year":"1995","unstructured":"Wolfe F, Ross K, Anderson J, Russell IJ, Herbert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheumatol. 1995;38:19\u201328.","journal-title":"Arthritis Rheumatol"},{"key":"60_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3899\/jrheum.180083","volume":"46","author":"F Wolfe","year":"2018","unstructured":"Wolfe F, Walitt MD, Rasker J, Hauser W. Primary and secondary fibromyalgia are the same: the universality of polysymptomatic distress. J Rheumatol. 2018;46:204\u201312.","journal-title":"J Rheumatol"},{"key":"60_CR54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"K Yaseen","year":"2017","unstructured":"Yaseen K, Kaouk S, Bork D, Wilke WS, Gota C. Polysymptomatic distress scale, widespread pain index, and symptoms severity scale, and their correlates in 169 patients with fibromyalgia syndrome. Ann Rheum Dis. 2017;76:386.","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-021-00060-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00060-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T06:03:28Z","timestamp":1674972208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-021-00060-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1186\/s42238-021-00060-6","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee of Eastern Piedmont. All patients provided informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}